Reported Saturday, Daiichi Sankyo And Merck's Ifinatamab Deruxtecan Shows Response Rates In Extensive-Stage Small Cell Lung Cancer In Phase 2 IDeate-Lung01 Trial
Reported Saturday, Daiichi Sankyo And Merck's Ifinatamab Deruxtecan Shows Response Rates In Extensive-Stage Small Cell Lung Cancer In Phase 2 IDeate-Lung01 Trial
根據週六報道，默沙東和默克共同研發的Ifinatamab Deruxtecan在第2階段IDeate-Lung01試驗中顯示出廣泛期小細胞肺癌的治療有效率。
- Objective response rate of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
- 12 mg/kg selected as optimal dose for extension part of IDeate-Lung01 phase 2 trial and recently initiated IDeate-Lung02 phase 3 study
- 在預先治療的患者中，第一三共和默克的ifinatamab deruxtecan在12 mg/kg劑量下的客觀緩解率爲54.8％
- 12 mg/kg 被選爲 Ideate-Lung01 2 期試驗延期部分的最佳劑量，最近啓動了 Ideate-Lung02 3 期研究